Sabrina Uehlein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sabrina Uehlein has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Ann-Sophie Silber-Peest
1 shared publication- Anna Frey
Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany
1 shared publication - Armin Saalmüller
Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine, Vienna, Austria
1 shared publication - Florian Schnitter
University Hospital Würzburg, Department of Internal Medicine I, Würzburg, Germany
1 shared publication - Friederike Löffler
Department of Cardiology and Angiology, Hannover Medical School
1 shared publication Janina Flößer
Institute for Virology and Immunobiology, University of Würzburg , Würzburg
1 shared publication
Latest Publications
- 15 November 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (10) , 2473-2488
Human-like Response of Pig T Cells to Superagonistic Anti-CD28 Monoclonal Antibodies
Because of its size, anatomical similarities, and now also accessibility to genetic manipulations, pigs are used as animal models for human diseases and immune system development. However, expression and function of CD28, the most important costimulatory receptor expressed by T cells, so far is poorly understood in this species. Using a newly generated mAb (mAb 3D11) with specificity for pig CD28, we detected CD28 on CD8+ and CD4+ αβ T cells. Among γδ T cells, CD28 expression was restricted to a small CD2+ subpopulation of phenotypically naive cells. Functionally, CD28 ligation with mAb 3D11-costimulated porcine T cells, enhanced proliferation and cytokine secretion in vitro. We used a second, likewise newly generated but superagonistic, anti-CD28 mAb (CD28-SA; mAb 4D12) to test the function of CD28 on porcine T cells in a pilot study in vivo. Injection of the CD28-SA into pigs in vivo showed a very similar dose-response relationship as in humans (i.e., 100 µg/kg body weight [BW]) of CD28-SA induced a cytokine release syndrome that was avoided at a dose of 10 µg/kg BW and below. The data further suggest that low-dose (10 µg/kg BW) CD28-SA infusion was sufficient to increase the proportion of Foxp3+ regulatory T cells among CD4+ T cells in vivo. The pig is thus a suitable animal model for testing novel immunotherapeutics. Moreover, data from our pilot study in pigs further suggest that low-dose CD28-SA infusion might allow for selective expansion of CD4+ regulatory T cells in humans. Key Points CD28 is a costimulatory receptor expressed by porcine T cells. Superagonistic anti-CD28 mAbs elicit a human-like response in porcine T cells.
- 15 November 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (10) , 2473-2488
Human-like Response of Pig T Cells to Superagonistic Anti-CD28 Monoclonal Antibodies
Because of its size, anatomical similarities, and now also accessibility to genetic manipulations, pigs are used as animal models for human diseases and immune system development. However, expression and function of CD28, the most important costimulatory receptor expressed by T cells, so far is poorly understood in this species. Using a newly generated mAb (mAb 3D11) with specificity for pig CD28, we detected CD28 on CD8+ and CD4+ αβ T cells. Among γδ T cells, CD28 expression was restricted to a small CD2+ subpopulation of phenotypically naive cells. Functionally, CD28 ligation with mAb 3D11-costimulated porcine T cells, enhanced proliferation and cytokine secretion in vitro. We used a second, likewise newly generated but superagonistic, anti-CD28 mAb (CD28-SA; mAb 4D12) to test the function of CD28 on porcine T cells in a pilot study in vivo. Injection of the CD28-SA into pigs in vivo showed a very similar dose-response relationship as in humans (i.e., 100 µg/kg body weight [BW]) of CD28-SA induced a cytokine release syndrome that was avoided at a dose of 10 µg/kg BW and below. The data further suggest that low-dose (10 µg/kg BW) CD28-SA infusion was sufficient to increase the proportion of Foxp3+ regulatory T cells among CD4+ T cells in vivo. The pig is thus a suitable animal model for testing novel immunotherapeutics. Moreover, data from our pilot study in pigs further suggest that low-dose CD28-SA infusion might allow for selective expansion of CD4+ regulatory T cells in humans. Key Points CD28 is a costimulatory receptor expressed by porcine T cells. Superagonistic anti-CD28 mAbs elicit a human-like response in porcine T cells.